Nightingale introduces combination of its proprietary blood test and genomics: acquires Finnish genetic testing company Negen and launches international centre of excellence for genomic data analysis
Company release, Inside information18 January 2022 at 9:20 a.m. (EET) Nightingale Health Plc (“Nightingale”) announces today that the company will take a major step towards its mission of empowering people to make the best decisions for their own health by combining Nightingale’s proprietary blood test with genomics. This expansion is accelerated by acquiring a Finnish genetic testing company Negen Ltd. (“Negen”) and launching an international excellence centre focusing on genetic data analysis. The first products integrating Nightingale’s proprietary blood test and genomic data will